drugset
drugset / Trial / NCT00352027

Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma

NCT00352027 ↗

Phase 2 Completed 81 enrolled St. Jude Children's Research Hospital
NaSingle-groupOpen-labelTreatment

Summary

The main purpose of this protocol is to estimate the percentage of patients with intermediate risk Hodgkin lymphoma who will survive free of disease (Event-free survival) for three years after treatment with multi-agent chemotherapy (Stanford V) and low-dose, tailored-field radiation therapy. The hypothesis being studied is that this treatment will result in more than 80% of patients being alive and free of disease three years after starting treatment.

Timeline

Start
2006-07-20
Primary completion
2015-05
Completion
2022-11-15

Drugs

EvaluationDrugModalityDoseRoute
Background Bleomycin Unknown 5 iu Intravenous
Background Cyclophosphamide Other / unclassified 650 mg/m2 Intravenous
Background Doxorubicin Other / unclassified 25 mg/m2 Intravenous
Background Etoposide Small molecule 60 mg/m2 Intravenous
Background Prednisone Other / unclassified 40 mg/m2 Oral
Background Vinblastine Small molecule 6 mg/m2 Intravenous
Background Vincristine Small molecule 1.4 mg/m2 Intravenous
Background filgrastim Protein / enzyme biologic 5 ug/kg Subcutaneous
Background mechlorethamine Small molecule 6 mg/m2 Intravenous

Indications

Hodgkins lymphoma